KRAS and neoplasm: In our analysis, using utility scores based on EQ-5D assessments collected during the phase 3 study, patients with wild-type KRAS tumours receiving panitumumab+BSC compared with patients on BSC alone had 6.5 more quality-adjusted weeks for PFS.